Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma [6]

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 5, 2007, Pages 579-580

  Ziemssen, Focke ^a   Voelker, Michael ^a   Altpeter, Elke ^a   Bartz schmidt, Karl U ^a   Gelisken, Faik ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RUTHENIUM;

ADULT; BRACHYTHERAPY; CANCER MORTALITY; CASE REPORT; CHOROID MELANOMA; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFORMED CONSENT; LETTER; LIVER METASTASIS; MALE; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RADIATION INJURY; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULOPATHY; TREATMENT OUTCOME; TUMOR LOCALIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; CHOROID NEOPLASMS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MELANOMA; MIDDLE AGED; RADIATION INJURIES; RETINA; RUTHENIUM RADIOISOTOPES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 34547424284     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2007.00899.x     Document Type: Letter

References (5)

1. Gunduz K, Shields CL, Shields JA et al. (1999): Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 117: 609-614.
2. Missotten GS, Notting IC, Schlingemann RO et al. (2006): Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 124: 1428-1434.
3. Shields CL, Demirci H, Dai V et al. (2005): Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 25: 868-874.
4. Spandau UHM, Ihloff AK & Jonas JB (2006): Intravitreal bevcacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84: 555-556.
5. Tas F, Duranyildiz D, Oquz H, Camlica H, Xasasever V & Topuz E (2006): Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16: 405-411.